Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

3.77
-0.2200-5.51%
Post-market: 3.770.00000.00%19:24 EDT
Volume:19.52K
Turnover:73.27K
Market Cap:10.19M
PE:-0.94
High:3.82
Open:3.81
Low:3.70
Close:3.99
52wk High:43.50
52wk Low:3.70
Shares:2.70M
Float Shares:2.48M
Volume Ratio:0.43
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0100
EPS(LYR):-8.5567
ROE:-207.37%
ROA:-90.39%
PB:1.02
PE(LYR):-0.44

Loading ...

Intensity Therapeutics Inc - Submits Protocol Amendment to Swissmedic and Swiss Ethics Committee to Resume Invincible-4 Study Enrollment

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics Inc - Preliminary Invincible-4 Study Shows 71.4% Pcr With Int230-6 Plus Soc, 33% With Soc Alone

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics regains Nasdaq compliance

TIPRANKS
·
Mar 06

Intensity Therapeutics Regains Nasdaq Minimum Bid Price Compliance

Reuters
·
Mar 06

Intensity Therapeutics Inc trading halted, news pending

TIPRANKS
·
Feb 19

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Feb 19

BRIEF-Intensity Therapeutics Announces Reverse Stock Split

Reuters
·
Feb 13

Intensity Therapeutics Implements 1-for-25 Reverse Stock Split

Reuters
·
Feb 13

BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities

Reuters
·
Jan 13

Intensity Therapeutics Inc. Outlines 2026 Strategy: Pursuing Additional Peer-Reviewed Publications, Advancing Regulatory Engagement, Opportunistically Raising Capital, and Planning Phase 3 Breast Cancer Study Initiation

Reuters
·
Jan 13

Intensity Therapeutics Inc - Plans to File Protocol Amendment for Invincible-4 Study and Reinitiate Enrollment in Q1 2026

THOMSON REUTERS
·
Jan 13

Intensity Therapeutics Inc: to Raise Additional Capital During 2026 to Reinitiate Patient Enrollment and Site Activations in Invicible-3 Study

THOMSON REUTERS
·
Jan 13

Intensity Therapeutics Inc. Releases Clinical Data on Anthracycline-Free Treatment for Early-Stage Triple Negative Breast Cancer

Reuters
·
Dec 18, 2025

Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial

Reuters
·
Dec 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret

Reuters
·
Dec 05, 2025

BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension

Reuters
·
Dec 05, 2025

BRIEF-Intensity Therapeutics Granted 180-Day Extension

Reuters
·
Dec 05, 2025

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement

THOMSON REUTERS
·
Dec 05, 2025

BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing

Reuters
·
Dec 04, 2025